Novo Nordisk will use the DKK 8.5 billion (US$1.2 billion) to build a new modular and flexible production facility in Odense, Denmark, that will produce multiple products for rare diseases.
SmithGroup's Wayne Barger discusses his expectations for more ambulatory facilities and merger activity in 2025 for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback